Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-07-02
DOI
10.1111/dom.13823
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes
- (2018) Yochai Birnbaum et al. CARDIOVASCULAR DRUGS AND THERAPY
- Mitochondrial dysfunction in diabetic kidney disease
- (2018) Josephine M. Forbes et al. Nature Reviews Nephrology
- The Warburg Effect in Diabetic Kidney Disease
- (2018) Guanshi Zhang et al. SEMINARS IN NEPHROLOGY
- Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet
- (2018) Susumu Takagi et al. Journal of Diabetes Investigation
- Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component?
- (2018) Francesco Prattichizzo et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients
- (2018) Laween Uthman et al. Frontiers in Physiology
- Mitochondrial energetics in the kidney
- (2017) Pallavi Bhargava et al. Nature Reviews Nephrology
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
- (2016) Sunder Mudaliar et al. DIABETES CARE
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mitochondrial Hormesis and Diabetic Complications: Figure 1
- (2015) Kumar Sharma DIABETES
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mitochondrial dysfunction and mitophagy: the beginning and end to diabetic nephropathy?
- (2013) G C Higgins et al. BRITISH JOURNAL OF PHARMACOLOGY
- AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function
- (2013) Laura L. Dugan et al. JOURNAL OF CLINICAL INVESTIGATION
- Metabolomics Reveals Signature of Mitochondrial Dysfunction in Diabetic Kidney Disease
- (2013) K. Sharma et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- A Mitochondrial Protein Compendium Elucidates Complex I Disease Biology
- (2008) David J. Pagliarini et al. CELL
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now